Loading…
Loading…
THE WOODLANDS, Texas, Sept. 10, 2026 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality" or the "Company") (Nasdaq: TH), one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, today announced that it has closed its previously announced underwritten, secondary offering (the "Offering") of 14,000,000 shares of its common stock, par value $0.0001 per share (the "Common Stock"), held by Arrow Holdings S.
Back-to-school spending is set to hit a record $146.8 billion in 2026, benefiting value-focused retailers, AI tools and semiconductor ETFs.
Advanced Micro Devices Inc (NASDAQ:AMD) stock is moving 2.1% lower this morning, brushing off an "overweight" initiation from Piper Sandler.
Macy's, Inc. delivered strong Q2 results, beating revenue and EPS expectations, and I reiterate a buy rating despite recent share price weakness. M's FY 2026 guidance was raised, with net sales targeted at $21.675–$21.825 billion and adjusted EPS of $2.15–$2.35, reflecting management confidence. M stock's valuation remains compelling with an 18.4% FCF yield and potential upside to $26/share, though macro headwinds like fuel costs and rates persist.
Vancouver, British Columbia – TheNewswire - September 10, 2026 – WestGold Metals Corp. (" WestGold " or the " Company ") (CSE: WGM; OTCQB: WGMTF; FSE: V0U) is pleased to announce that, further to its August 18, 2026 news release, it has completed its review of the historical technical database for its Idaho Portfolio, including a 2025 induced polarization (" IP ") survey at Amie and a 2024 independent structural mapping study, both commissioned by IDEX Metals Corp. (" IDEX "). The Company also announces an expansion of its claim package and the commencement of a surface exploration program. Highlights
VANCOUVER, BC / ACCESS Newswire / September 10, 2026 / Green Bridge Metals Corporation (CSE:GRBM)(OTCQB:GBMCF)(FWB:J48, WKN: A3EW4S) ("Green Bridge" or the "Company") is pleased to report the final assay results from its Phase 1 diamond drill program at the Titac Project, located within the Company's South Contact Zone Project in northeastern Minnesota, U.S.A. (Figure 1).
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2026) - Toogood Gold Corp. (TSXV: TGC) (OTCQB: TGGCF) (FSE: D3P) ("Toogood" or the "Company") announces the definition of two priority, multi-kilometre drill-target corridors, the Widowmaker and Pacifico trends, following completion of 1:5,000-scale geological mapping at its Table Mountain Gold-Silver Project ("Table Mountain" or the "Project") in Lincoln County, Nevada. Highlights Phase 1 mapping completed: Detailed 1:5,000-scale mapping has refined the volcanic stratigraphy, hydrothermal alteration, structural framework and epithermal veining across the Project; Widowmaker trend defined over more than 5 km: A major arcuate structural corridor extending through the core of the epithermal system and hosting a metre-scale epithermal vein intermittently exposed over more than 1 km, with associated float extending along a trend of more than 2 km; Pacifico trend defined over more than 5 km: A subparallel arcuate structural corridor located approximately 500 m east of Widowmaker and comprising multiple prospective faults hosting epithermal veins; Multiple priority drill targets identified: Kilometre-scale bends, stepovers, jogs and structural intersections define high-priority areas for drill testing; Evidence of boiling and system preservation: Vein and silica textures indicate widespread boiling and suggest that the prospective gold-silver interval may be preserved at depth; Exploration advancing: Field acquisition for UAV magnetics and ground gravity, together with soil and rock sampling, has been completed, with a 15 line-kilometre CSAMT survey scheduled for September; and Drill permitting initiated: Notice of Intent ("NOI") work is underway in support of the Company's planned maiden drill program.
Viking Therapeutics is studying its weight-loss drug candidate in phase 3 trials. Today Eli Lilly and Novo Nordisk dominate the market, but high demand suggests there's room for additional players.